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was offset by administration every second day of aspirin 325
mg. Furthermore, hyperfibrinogenemia has been associated
with plaque features, such as thrombosis, macrophage foam
cell infiltration of the fibrous cap, and decrease in cap thick-
ness in carotid artery plaques.7 It is unknown whether the
level of LDL cholesterol in plasma or use of aspirin directly
affects the density of macrophages in carotid artery athero-
sclerotic lesions or whether moderately elevated levels of
acute-phase reactants CRP and orosomucoid are markers of
macrophages in atherosclerotic plaques.
Echolucency of carotid artery atherosclerotic plaques
evaluated by B-mode ultrasound imaging is associated
with lipid-rich or thrombotic plaques,8 which in coronary
arteries are believed to be especially prone to rupture and
cause myocardial infarction.2-5 Whether echolucency pre-
dicts plaques rich in macrophages is, however, unknown
presently. 
In this study of patients with carotid artery atheroscle-
rosis and previous ipsilateral hemispheric neurologic
symptoms, we tested whether plaque echolucency, ele-
vated plasma lipoproteins, elevated acute-phase reactants,
and aspirin use were associated with macrophage density
in carotid artery plaques. 
MATERIAL AND METHODS
Subjects. The study included 106 patients (71 men
and 35 women, median age 61 years) referred for carotid
artery ultrasound examination and carotid endarterectomy
Atherosclerosis is an inflammatory disease.1 The domi-
nating mechanism is macrophage accumulation in athero-
sclerotic plaques caused by accumulation of low-density
lipoprotein (LDL). Macrophages at sites of ongoing
inflammation in advanced atherosclerotic plaques may pre-
cipitate plaque rupture, leading to acute clinical events such
as myocardial infarction2-5 and ischemic stroke. The
macrophages are often situated in the core and shoulders of
the plaque.3 Levels in the upper normal range of C-reactive
protein (CRP), an acute-phase reactant and marker of sys-
temic inflammation, has been shown to predict future
ischemic stroke and myocardial infarction6; this association
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Objective: Atherosclerosis may be regarded as an inflammatory disease dominated by macrophages. We tested whether
macrophages in carotid artery atherosclerotic plaques are associated with echolucency on B-mode ultrasound imaging,
lipid levels, inflammatory markers, and aspirin use.
Methods: We studied 106 patients undergoing carotid endarterectomy having ≥50% carotid artery stenosis and previous
ipsilateral hemispheric neurologic symptoms.
Results: Macrophages were particularly common in plaques with a high content of lipid and hemorrhage and, conversely,
rare in plaques dominated by calcification and fibrous tissue. Macrophage density in carotid artery plaques classified by
B-mode ultrasound imaging as echolucent (n = 56), intermediate (n = 25), or echorich (n = 25) was 1.8% ± 0.2%, 1.5%
± 0.4%, and 1.0% ± 0.2% (±SE), respectively (analysis of variance, P = .02). A computer-generated measure of plaque
echolucency, gray-scale median, was associated with increased macrophage density (r = –0.31; P = .002). Furthermore,
plasma and low-density lipoprotein cholesterol levels were associated with carotid artery macrophage density (r = 0.26,
P = .008 and r = 0.23, P = .02); this was most pronounced in patients with lipid-rich plaques. Macrophage density was
not associated with plasma levels of acute-phase reactants. Finally, macrophage density in carotid artery plaques of users
(n = 55) and nonusers of aspirin (n = 51) was 1.2% ± 0.2% and 1.8% ± 0.2% (t test, P = .01). 
Conclusions: Increased macrophage density in carotid atherosclerotic plaques was associated with lipid content, plaque
echolucency, and increased plasma and low-density lipoprotein cholesterol levels. Furthermore, use of aspirin was asso-
ciated with reduced macrophage density in carotid artery plaques. (J Vasc Surg 2002;35:137-45.)
at Rigshospitalet, National University Hospital in
Copenhagen. All patients had a ≥50% carotid artery steno-
sis and previous ipsilateral hemispheric neurologic symp-
toms: minor ischemic stroke (n = 39 [37%]), transient
ischemic attack (n = 53 [50%]), or amaurosis fugax (n = 14
[13%]). Patients with excessive alcohol intake, serious liver
disease, cancer, infectious disease, systemic inflammatory
disease, or cerebral hemorrhage were excluded. One or
more computed tomography scans were obtained to
exclude hemorrhage as the cause of neurologic symptoms.
The 106 patients were consecutively enrolled among
patients scheduled for carotid endarterectomy, who gave
blood for measurement of acute-phase reactants and
carotid artery tissue for histologic examinations. Of these
106 patients, 58 had a lipid tolerance test performed and
were also included in a previous study.8 Aspirin dosage was
100 to 150 mg daily. The compliance with aspirin therapy
was solely validated through patient history. With regard
to lipid-lowering therapy, patient history together with
measurement of plasma lipid levels was used to assess com-
pliance. The study was approved by the medical ethics
committee for Copenhagen and Frederiksberg Counties
(KF 01-062/94), and all patients gave informed consent.
Ultrasound examination (n = 106). With an
Apogee Interspec 400 scanner (ATL Ultrasound, Bothell,
Wash) and a 5- to 10-MHz linear array transducer, longi-
tudinal B-mode images with the best image of the carotid
artery plaques on the symptomatic side were classified on-
line. The plaques were subjectively evaluated as reflecting
the ultrasound waves strongly (echorich), weakly (echolu-
cent), or roughly equal to the reflectance of the far wall
beneath the normal intima-media complex (intermediate;
Fig 1). The carotid artery bifurcation was captured in the
center of the ultrasound image and was also marked on the
corresponding section removed during endarterectomy for
histologic specimens. Furthermore, video recorded B-
mode images in 100 patients were also processed with the
software program Image-Pro Plus version 1.2.01 for
Windows (Media Cybernetics, Silver Spring, Md)8: the
carotid artery plaque was outlined, and the gray-scale value
of each pixel in the region (0 to 255; 0 = black, 255 =
white) was used to generate a median and mean value.
These values were adjusted for the gray-scale values of
blood (median, 0) and the far wall adventitia layer (median,
190) in each patient.9 In case of acoustic shadowing (total
reflectance of the ultrasound beam, hiding everything
beneath the reflecting plaque), the outline of the plaque
did not include this shadow region. In six patients recorded
B-mode images were lost because of technical problems.
The degree of stenosis was determined by routine Doppler
criteria. Ultrasound examinations, subjective evaluations,
and computer processing of images were all performed by
a single experienced ultrasonographer (MLMG) who was
unaware of the results from acute-phase reactant and lipid
measurements, as well as histologic examination.
Intraobserver variation for gray-scale measurements at the
median level of 52 was 6% when 58 consecutive images
were reprocessed by the same ultrasonographer (MLMG)
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Fig 1. A, Subjectively evaluated echorich carotid artery plaque
reflects ultrasound beam strongly. B, Intermediate carotid artery
plaque. C, Subjectively evaluated echolucent carotid artery
plaque reflects ultrasound beam weakly, thereby hard to see on B-
mode imaging without color-flow to visualize borders of plaque.
CCA, Common carotid artery; ICA, internal carotid artery.
Arrows indicate plaques. 
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to obtain a second set of gray-scale values.8 Interobserver
variability measure for subjective evaluation of plaque
echogenicity had a kappa value of 0.61 when evaluations
performed by MLMG and HS were compared. In addi-
tion, interobserver variability for gray-scale measurement
has a coefficient of variation of 5% among four different
observers.9 In this series, subjectively evaluated echorich (n
= 25), intermediate (n = 25), and echolucent (n = 56)
plaques had median gray-scale (objectively evaluated) lev-
els (mean [interquartile range]) of 97 (47 to 132), 68 (36
to 72), and 35 (10 to 47), respectively.
Histologic examination (n = 106). During endar-
terectomy carotid artery plaques were removed in one
piece and cut open in the vertical direction. After the spec-
imen was cut transversely into 3-mm–thick blocks (4 to 14
per patient), 4-µm sections were cut from the individually
labeled blocks and stained with hematoxylin and eosin,
Van Gieson’s stain for connective tissue, and Verhoeff ’s
stain for elastin. Plaque constituents (atheromatous lipid-
rich gruel, hemorrhage, calcification, thrombus, and
fibrous tissue) in all sections were measured morphomet-
rically by a single experienced pathologist (BMW), who
used a Leitz Texture Analyzing System (TAS, Cambridge,
United Kingdom). For repeated measurements of plaque
lipid and fibrous tissue content (n = 10), coefficient of
variations were 4% and 2% at the levels of 38% and 61%,
respectively.8
For detection of macrophages,10 in each endarterec-
tomy specimen the histologic section with the largest area
was identified, and new sections were cut from the corre-
sponding paraffin blocks and from the two adjacent blocks
(upstream and downstream). We chose this area of the
plaque because it is anticipated to contain the most inflam-
mation11-13 and consequently the most macrophages.
After rehydration and proteolytic pretreatment with
trypsin, these three sections were immunostained by
sequential incubation with blocking rabbit serum (X902;
Dako, Copenhagen, Denmark), primary monoclonal anti-
body against human macrophages (CD68, PG-M1-
Dako), secondary biotinylated rabbit antibody (E354,
Dako), ABComplex-alkaline phosphatase (K376, Dako),
chromogen substrate (SK-5100, Vector Laboratories,
Burlingame, Calif), and counterstain (hematoxylin) (Fig
2). For quantitative determination of macrophages in
plaques, microscopic images of the immunostained sec-
tions were captured with a Sony three-chip color video
camera (Tokyo, Japan) and analyzed blindly by use of
automated image analysis equipment. After brightness and
color tone of the captured images were adjusted, a 24-
color palette containing three red colors specific for the
macrophage stain was applied in PaintShop Pro 5
(Minnetonka, Minn). The percentage of plaque occupied
by the macrophage-specific colors was quantitated in
SigmaScan Pro 3.0 (Jandel Corporation, San Rafael,
Calif). An average value for the macrophage density in the
three sections was used in the statistical analyses. The same
pathologist reexamined 20 randomly chosen plaques 6
months later for content of macrophages and was blinded
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 1 Grønholdt et al 139
to the first examination results. Coefficients of variation
for macrophage density in carotid artery plaques was 0.2%
with a mean bias of –0.1 (95% confidence interval [CI],
–0.3 to 0.2) at the level of 2%. The pathologists were
unaware of results from acute-phase reactant and lipid
measurements and ultrasound examination.
Acute phase reactants (n = 106). Acute phase reac-
tants were measured with patients in the fasting state at
the same time as the ultrasound examination and immedi-
Fig 2. Macrophage-rich carotid artery plaque. A, Immuno-
staining of carotid artery plaque: macrophages appear red with
macrophage-specific antibody PG-M1. B, As control, no staining
for macrophages is seen, adding irrelevant control antibody X0931
from DAKO instead of PG-M1. C, Total scale bar length = 1 mm.
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ately before endarterectomy, but at least 3 months after
episodes of myocardial infarction. Levels of highly sensi-
tive (hs) CRP and orosomucoid (acid α1-glycoprotein)
were measured by conventional nephelometry (Behring
Diagnostica, Franklin Lakes, NJ). The assays were maxi-
mally sensitive within the reference ranges for the two
assays, that is hsCRP < 5 mg/L and orosomucoid 40 to
130 mg/dL, respectively. Plasma samples were kept at
–80° C from sampling until measurement in all patients
and analyzed in a single batch at the end of the experiment
with only one calibration used. Coefficient of variation for
hsCRP measurements at the levels of 29 and 2 mg/L were
3% and 4% (n = 20). Coefficient of variation for orosomu-
coid measurements at the levels of 83 and 8 mg/dL were
3% and 4% (n = 20).
Lipid measurements (n = 103). Blood samples were
collected the day before carotid endarterectomy; choles-
terol and triglycerides in plasma and cholesterol in LDL
and high-density lipoprotein (HDL) were determined
enzymatically (CHOD PAP and GPO-PAP; Boehringer
Mannheim, Mannheim, Germany) after precipitation of
other lipoproteins.
Statistical analysis. Student’s t test, Mann Whitney
U test (if unequal variances), analysis of variance
(ANOVA), unifactorial linear regression, and analysis of
covariance (ANCOVA; forced entry) were performed with
the Statistica for Windows (Stat Soft, Tulsa, Okla).
Allowance for lipid-lowering medication, aspirin use, and
plaque lipid content was done for all analyses by use of
ANCOVA. To approach a normal distribution before
parametric testing, histologic plaque content and hsCRP
levels were transformed logarithmically, whereas plaque
gray-scale values and plaque macrophage density were
square-root transformed.
RESULTS
Characteristics of patients are listed in Table I. Carotid
artery plaque morphology on histology and ultrasonogra-
phy levels of acute-phase reactants, and use of medication
potentially affecting macrophages in carotid artery plaques
are given in Table II.
Plaque morphology and macrophage density.
Only a few percent of all plaque tissue was occupied by
macrophages. Macrophages were particularly common in
plaques with a high content of lipid and hemorrhage and,
conversely, rare in plaques dominated by calcification and
fibrous tissue (Table III). These results were similar when
the analysis was adjusted for use of either lipid-lowering
medication or aspirin. The degree of carotid artery steno-
sis was not significantly correlated to macrophage density
(P = .74).
Ultrasonic echolucency and macrophage density.
Macrophage density in carotid artery plaques differed
according to the subjective evaluation of plaque
echogenicity (ANOVA, P = .02): individuals with echolu-
cent plaques had more macrophages than individuals with
echorich plaques (Fig 3; t test, P = .01). Furthermore,
computer-generated estimates of plaque echogenicity,
gray-scale mean or median standardized for the gray-scale
level of blood and adventitia were inversely related to
macrophage density of plaques (Table IV): The more
echolucent (ie, the lower the gray-scale value), the more
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Table I. Characteristics of 106 patients at the time of
carotid endarterectomy
±SE Frequency
Cardiovascular risk factors
Age (y) 61 ± 1
Current smoker (%) 56
Past smoker (%) 28
Hypertension (%) 49
Diabetes (%) 7
Family history* (%) 38
BMI (kg/m2) 25 ± 0.4
Plasma cholesterol (mmol/L) 6.5 ± 0.1
Plasma triglycerides (mmol/L) 1.9 ± 0.1
HDL cholesterol (mmol/L) 1.5 ± 0.1
LDL cholesterol (mmol/L) 3.6 ± 0.1
Previous disease
Amaurosis fugax (%) 13
TIA (%) 50
Stroke (%) 37
MI (%) 10
Angina pectoris (%) 6
Heart failure (%) 3
BMI, Body mass index; TIA, transient ischemic attack; MI, myocardial
infarction more than 3 months ago.
*Family history, first degree relative experienced MI or stroke before 
age 60. 
Table II. Carotid artery plaque histomorphometry and
ultrasound imaging, acute-phase reactants, and use of
medication in patients undergoing carotid endarterectomy
±SE Frequency
Histomorphometry 
Macrophage density (%) 1.6 ± 0.2
Plaque lipid (%) 40.4 ± 1.3
Plaque hemorrhage (%) 0.5 ± 0.1
Plaque calcification (%) 1.2 ± 0.1
Plaque fibrous tissue (%) 57.9 ± 1.3
B-mode ultrasonography
Echolucent (%) 24
Intermediate (%) 24
Echorich (%) 52
Gray-scale mean 70.0 ± 4.8
Gray-scale median 58.3 ± 5.6
Doppler ultrasonography
Carotid artery stenosis 31
50% to 79% (%)
Carotid artery stenosis 69
80% to 99% (%)
Acute phase reactants 
HsCRP (mg/L) 8.2 ± 1.4
Orosomucoid (mg/dL) 120 ± 3.4
Use of medication
Lipid-lowering medication (%) 19
Aspirin (%) 52
macrophages in the plaque. The inverse association
between macrophage density and plaque gray-scale mean
or median was also seen, when the statistical analysis was
adjusted for use of lipid-lowering medication, aspirin, or
relative plaque lipid content (Table IV).
LDL and macrophage density. Both plasma choles-
terol and LDL cholesterol levels were positively associated
with macrophage density in carotid artery plaques (r =
0.20, P = .046 and r = 0.25, P = .01; Table V). Plasma
triglycerides and HDL cholesterol levels were not associ-
ated with macrophage density in plaques. These results
were similar after allowing for lipid-lowering treatment or
aspirin use. After stratifying for plaque lipid content (over
and under mean plaque lipid), plasma and LDL choles-
terol were strongly and positively associated with
macrophage density in lipid-rich plaques but not in lipid-
poor plaques (Table V).
Acute-phase reactants and macrophage density.
Orosomucoid and hsCRP levels were not associated with
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macrophage density on linear regression analysis (r = 0.13,
P = .20 and r = 0.07, P = .48). The results were similar
when the analysis allowed for the significant association of
macrophage density and time-interval from the last neuro-
logic symptom or coronary infarction to surgery and mea-
surement of acute-phase reactants (r = –0.23, P = .02). 
Aspirin, lipid-lowering medication, and macrophage
density. Use of aspirin 100 to 150 mg per day was associ-
ated with reduced macrophage density in carotid artery
plaques, when data were unadjusted or adjusted for lipid-
lowering medication (Fig 4). Lipid-lowering medication was
not associated with macrophage density in carotid artery
plaques when data were unadjusted or when adjusted for use
of aspirin (data not shown). It should be noted, however,
that patients receiving lipid-lowering medication had plasma
cholesterol levels of 7.0 ± 0.6 mmol/L, similar to the level
of 6.5 ± 0.2 mmol/L in untreated patients (t test, P = .27).
Macrophage density in histologic sections. Macro-
phage density in the three different sections (x ± SE) were
Table III. Correlation of carotid artery plaque lipid, plaque hemorrhage, plaque calcification, and plaque fibrous tissue
versus macrophage density in 106 carotid artery plaques
% Macrophage density Adjusted for lipid lowering medication Adjusted for aspirin 
r P value r P value* r P value*
% Plaque lipid 0.27 .004 0.28 .002 0.27 .003
% Plaque hemorrhage 0.29 .002 0.29 .002 0.28 .002
% Plaque calcification –0.23 .01 –0.25 .008 –0.19 .04
% Plaque fibrous tissue –0.27 .004 –0.26 .005 –0.26 .006
*By ANCOVA.
Fig 3. Macrophage density in carotid artery plaques with different echogenicities. Values are mean ± SE.
Post hoc t tests for three two-group comparisons are also shown.
upstream 2.0% ± 0.3%, middle 1.5% ± 0.2%, and down-
stream 1.5% ± 0.2%; the values in the three sections corre-
lated (downstream vs middle, r = 0.31, P < .001; upstream
vs middle, r = 0.50, P < .00001; downstream vs upstream,
r = 0.53, P < .00001). 
DISCUSSION
We observed that macrophage density in carotid
artery plaques is associated with echolucency on B-mode
ultrasound imaging, as well as with plasma cholesterol,
LDL cholesterol, and plaque lipid content. Moreover, use
of aspirin seemed to be associated with a reduced number
of macrophages in carotid artery plaques. None of these
observations have been reported previously. We chose to
investigate macrophages because they are the most domi-
nating cell type in atherosclerotic inflammatory infiltrates,
with up to 51% of all cells at the immediate site of plaque
rupture being macrophages.2-5,14 In contrast, only 6% of
all cells at sites of plaque rupture were T-lymphocytes and
mast cells.2-5,14 Little has been reported on a specific rela-
tionship between levels of cardiovascular risk factors and
composition of the atherosclerotic plaque in the vessel
wall.15,16 In one of the few immunohistochemical charac-
terizations of carotid artery plaques, Milei et al15 could
not find any correlations between risk factors and any
immunohistochemical finding in plaques.
Plaque echolucency evaluated both subjectively and
computer-assisted was associated with an increased
macrophage density in carotid plaques, though the corre-
lations were rather weak: roughly 9% (r2) of the variation
in macrophage density could be explained by variation in
plaque echogenicity. In this context it is also important to
note that B-mode ultrasound scanning naturally does not
detect macrophages directly but appears to be able to
identify plaques rich in macrophages. This finding could
be predicted because echolucency has been associated with
lipid and hemorrhage in the plaque8 and because plaque
lipid and plaque macrophage density was associated.2-5 It
is therefore possible that the association between echolu-
cency and macrophage density is not independent. In
other words, plaques with high lipid content are more
echolucent (true association), whereas macrophages are
associated with lipid-rich plaques. However, when adjust-
ing for plaque lipid content, independent associations
between echolucency and macrophage density were still
encountered. Echolucency also predicts occurrence of
ischemic stroke.17,18 Interestingly, in patients with previ-
ous symptoms, the relative risk of ischemic stroke during
4.4 years of follow-up was 1.0, 3.1, 4.2, and 7.9, in
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Table IV. Linear regression analysis of gray-scale mean
or median and their association with macrophage density
in 100 carotid artery plaques
% Macrophage density 
r P value
Standardized for blood 
and adventitia echogenicity*
Gray-scale mean –0.29 .004
Gray-scale median –0.31 .002 
Adjusted for lipid-lowering 
medication†
Gray-scale mean –0.29 .005
Gray-scale median –0.31 .003
Adjusted for aspirin†
Gray-scale mean –0.27 .008
Gray-scale median –0.30 .004
Adjusted for % plaque lipid†
Gray-scale mean –0.21 .03
Gray-scale median –0.23 .02
*Gray-scale value standardized for blood (0) and adventitia (190)
echogenicity in each patient before statistical analysis. 
†By ANCOVA.
Fig 4. Macrophage density in carotid artery plaques according to use of aspirin. Values are mean ± SE.
When ANCOVA was adjusted for use of lipid-lowering medication, P = .01. 
patients with computer-evaluated echorich 50% to 79%
stenotic, echorich 80% to 99% stenotic, echolucent 50% to
79% stenotic, and echolucent 80% to 99% stenotic carotid
artery plaques, respectively. Furthermore, lipid- and
macrophage-rich plaques are found to be more prone to
rupture and cause myocardial infarction in coronary arter-
ies,2-5 as well as neurologic symptoms in patients with
carotid artery stenosis.19-21 Our observation that the
amount of plaque lipid was greater in plaques with larger
macrophage density also supports this suggestion.
Hemosiderin-loaded macrophages are especially seen in
plaques with previous intraplaque hemorrhage after a rup-
ture of the fibrous cap.22 This is in accordance with our
finding that macrophage density also correlated with the
amount of hemorrhage in the plaque. There is also evi-
dence that arterial flow plays a role in the distribution of
different cell types: in a recent study by Dirksen et al,11
more macrophages and plaque ruptures were found
upstream compared with downstream of carotid artery
plaques which was also the case in our study.
Most studies regarding the role of inflammation in
atherosclerotic disease have focused on coronary artery
disease,2-5,14 but recently a study on carotid arteries has
shown a relationship between inflammatory cells, mainly
macrophages, and plaque rupture.12 Many proinflamma-
tory agents as precipitators of myocardial infarction have
been proposed, such as oxidized LDL cholesterol and
infection with Chlamydia pneumoniae, herpes simplex
virus, cytomegalovirus, or Helicobacter pylori.2 Oxidized
LDL attracts macrophages to and activates them in ather-
osclerotic plaques.3 Vulnerable coronary artery plaques
with macrophage infiltration have been found to be inde-
pendently associated with plasma cholesterol.23 This sup-
ports our findings of positive associations between plasma
and LDL cholesterol with macrophage density in carotid
artery plaques. Two possible mechanisms exist: (1) the
high cholesterol level is associated with a more lipid-rich
plaque, and this lipid-rich plaque contains more macro-
phages; or (2) high cholesterol level is directly associated
with more macrophages, regardless of lipid content in the
plaques. After stratification for lipid-rich plaques (≥mean
plaque lipid), the first mechanism was most plausible,
because plasma LDL then correlated better with
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macrophage density (Table V). However, because
atheroma formation evolves over a long period of time,
one-time spot measurement of plasma lipids may not accu-
rately reflect an association between inflammatory evolu-
tion of atheroma and lipoproteins. We did not measure
plasma lipids more than once and therefore cannot con-
firm the persistence of their elevated levels. 
In this study, use of cholesterol-lowering medication,
mostly statins, did not correlate with macrophage density
in carotid artery plaques. This lack of correlation was
expected, because plasma cholesterol was similar in treated
and untreated patients, and because treated patients
before start of medical treatment had even higher levels.
However, statins also exert antiinflammatory effects: in
recent animal and human studies, lipid-lowering diet24 or
statins25,26 reduced macrophage accumulation, oxidized
LDL, cell death, and matrix metalloproteinase activity and
increased collagen accumulation in the fibrous cap,
thereby probably stabilizing the plaques. 
Controversy exists on the potential antiinflammatory
effect of low-dose aspirin. Our patients received a low
dose of aspirin 100 to 150 mg on a daily basis, which is
known to inhibit platelet function and has a primarily
antithrombotic effect. Synthesis of proaggregatory throm-
boxane A2 in platelets is inhibited to a greater extent than
the production of the antiaggregatory prostacyclin in the
vessel wall.27 Because platelets have been shown to secrete
proinflammatory molecules, platelet inhibition by aspirin
may have additional antiinflammatory effects.28 Other
antiinflammatory effects of clinically relevant levels of
aspirin are inhibition of nuclear factor–kappa β activation,
vascular cell adhesion molecule-1, and E-selectin, and sub-
sequent monocyte adhesion in endothelial cells stimulated
by tumor necrosis factor–α.29 A 300-mg daily aspirin dose
reduces cytokine and CRP levels in patients with stable
angina.30 Furthermore, aspirin seems to promote synthe-
sis of antiinflammatory eicosanoids such as 15-epi-lipoxin
A4.31 These effects are independent of the action of
aspirin on prostaglandin synthesis via inhibition of
cyclooxygenases (COX) 1 and 2, where inhibition of COX
2 (ie, expressed by cytokines from macrophages) requires
166 times the concentration of aspirin in serum as inhibi-
tion of COX 1 (expressed by platelets).32 As a result,
Table V. Linear regression analysis of plasma lipoproteins association with macrophage density in all 103 carotid artery
plaques and stratified for lipid-rich plaques
% Macrophage Stratified for Adjusted for Adjusted for
density lipid-rich plaques* lipid-lowering medication† aspirin†
r P value r P value r P value r P value
Plasma cholesterol 0.2 .046 0.34 .01 0.2 .04 0.15 .13
LDL cholesterol 0.25 .001 0.49 .0001 0.24 .02 0.2 .02
HDL cholesterol -0.03 .79 0.02 .87 –0.01 .92 –0.030 .78
Plasma triglycerides 0.08 .41 0.20 .14 0.09 .37 0.04 .67
*≥plaque lipid mean (n=59).
†By ANCOVA.
aspirin dosages greater than 300 mg/d were previously
regarded as necessary to obtain an antiinflammatory
effect.33 According to recent evidence, however, lower
doses of aspirin also exert antiinflammatory effects.29-31
This could explain the decreased macrophage density seen
with aspirin usage in our patients; however, the associations
seen are quite weak and could be due to a type I error.
It is still not known whether CRP can be used as a
marker for atherosclerotic inflammatory activity, or as a
marker of systemic inflammation only.34,35 Danesh et al35
in a metaanalysis found that elevated CRP is associated
with increased risk of coronary artery disease.
Furthermore, elevation of CRP and serum amyloid A was
related to risk of coronary events for patients randomized
to placebo, whereas this relation was no longer significant
in patients treated with pravastatin in the Cholesterol and
Recurrent Events study.36 CRP levels in survivors of
myocardial infarctions were significantly reduced after 5
years of statin treatment compared with placebo.36 These
changes were unrelated to lipid alterations, indicating an
antiinflammatory effect of this drug.36 Only one study has
related acute-phase reactants (fibrinogen) with
histopathologic changes at plaque level.7 We did not find
a linear correlation between the acute-phase reactants
hsCRP and orosomucoid and macrophage density. 
The time interval from the latest neurologic symptom
or myocardial infarction to surgery and measurement of
acute-phase reactant and lipid levels in plasma did not seem
to influence the major correlations performed in this study.
It was important to exclude this potential confounder,
because we expected to find most macrophages at the time
closest to plaque rupture and a neurologic event, where the
ongoing inflammation in the plaque is expected to be
greatest.2-5 Furthermore, an inflamed, lipid-rich plaque is
believed to become more fibrotic or calcified and thereby
stabilizes with time after plaque rupture.2-5
An inherent problem with quantitative immunohisto-
chemistry is that the staining intensity does not only depend
on the amount of antigen present in the section, but also on
the thickness of the section and the staining procedure.
Although all effort is taken to keep these variables constant,
adjustment of brightness and color tone may be necessary
before measurement of an automated area. Although the
actual value may be questioned, this technique is repro-
ducible and reliable if the adjustment is performed blindly
and by the same observer, as in this study. Symptomatic
carotid artery plaques are large, all analyses were performed
under low-power magnification, and the adjustment was
guided by simultaneous microscopic examination of the
section. We used a monoclonal mouse antibody that specif-
ically stains monocyte/macrophages, but not other cell
types present in plaques (Dako PG-M1 [M0876]).
Macrophages present in simultaneously stained plaques
were used as positive control, and an irrelevant antibody
was used as negative control for PG-M1 (Dako X0931). In
conclusion, macrophage density appears to be associated
with echolucency of plaques and elevated levels of plasma
and LDL cholesterol, whereas levels of acute-phase reac-
tants do not predict macrophage density in carotid artery
plaques. It appears that risk factor assessment and B-mode
ultrasound imaging are useful tools in predicting
macrophages in vulnerable rupture-prone plaques, being
the most dominant inflammatory cell type herein.
Nevertheless, examination of plaques from asymptomatic
individuals is necessary before it can be postulated that the
development of symptoms correlates with plaque lipid con-
tent, macrophage density, or any other microscopic or bio-
chemical characteristic.
We appreciate technical assistance from Jens Wilhjelm,
Niels Wilenius, Hanne Damm, Anne Merete Bengtsen,
Ann Meisler, and Birgitte Søe Hansen.
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